Since the United States announced its support last month for temporarily suspending intellectual property (IP) protections on COVID-19 vaccines, momentum has grown behind efforts to expand vaccine supply and production worldwide. The United Nations has warned that stark vaccine inequality between nations continues to fuel the spread of COVID-19 and heightens the risk of variants that may evade existing vaccines.
Different governments have adopted varying strategies to address the challenge of vaccinating populations lacking sufficient doses. In October 2020, India and South Africa introduced a proposal at the World Trade Organization (WTO) seeking a temporary waiver of intellectual property rights related to COVID-19 vaccines and other coronavirus-related medical products. Their argument centers on the premise that waiving patents would enable more countries to manufacture urgently needed vaccine doses.
However, major pharmaceutical companies and countries including the United Kingdom, Canada, and Germany have opposed the waiver initiative. They cite concerns that such measures could undermine innovation incentives and highlight the limited availability of suitable manufacturing infrastructure required to scale up production effectively.
Globally, over 3 billion COVID-19 vaccine doses have been administered, according to data from Our World in Data. Yet, the vast majority of these doses have been delivered in wealthier nations, with less than two percent administered across Africa. This disparity has drawn criticism and calls for more equitable access.
“It’s such a chaotic situation,” said Yuanqiong Hu, legal adviser for the Access Campaign at Doctors Without Borders. “We see huge inequity globally. There’s a high level of concentration on who owns the technology and who produces it.”
Negotiations over the proposed waivers are set to resume at an informal WTO meeting, underscoring the intensifying debate around intellectual property rights in the context of the pandemic.
Intellectual property rights, which vary by country, are defined by the WTO as rights granted to creators over their “creations,” allowing them to prevent unauthorized use or to negotiate licensing fees. These rights cover inventions, artistic works, formulas, and more, and are protected through patents, trademarks, and copyrights. Biotech firms argue that such protections have incentivized the rapid development and production of COVID-19 vaccines.
The WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), in effect since 1995, is the most comprehensive multilateral agreement governing IP protections.
The waiver proposal by India and South Africa seeks to permit WTO member countries to opt out of enforcing patents and other IP rights related to health products and technologies for COVID-19. This includes diagnostics, therapeutics, vaccines, medical equipment, and their manufacturing methods. The waiver would provide legal space for countries to collaborate on research and development and shield them from litigation risks associated with non-compliance with TRIPS during the pandemic.
Importantly, the waiver is discretionary, allowing countries to decide whether to implement it. The proposal suggests the waiver remain in effect for at least three years from the date of adoption.
“An IP waiver doesn’t automatically remove all intellectual property rights relating to vaccines, PPE, ventilators and anything else,” explained Duncan Matthews, director at the Queen Mary Intellectual Property Research Institute in London. “It gives the discretion to particular countries to do that.”
He added, “We wouldn’t, for example, expect to see a waiver of IP in Europe, in the US or in other developed parts of the world. It would simply create an opportunity for middle and low-income countries to set aside those rights where they deem it necessary to increase supply and to scale up production.”
Global Debate Intensifies Over COVID-19 Vaccine Patent Waivers to Address Supply Inequities The push to temporarily waive intellectual property protections for COVID-19 vaccines has gained momentum following U.S. support, as global leaders grapple with vaccine inequity and the risk of new variants. India and S... Read the full IIPLA article: https://iipla.org/news/global-debate-intensifies-over-covid-19-vaccine-patent-waivers-to-address-supply-inequities